A Comprehensive Monograph on the 15-Valent Pneumococcal Conjugate Vaccine (Vaxneuvance)

Executive Summary

The 15-valent pneumococcal conjugate vaccine (PCV15), marketed globally as Vaxneuvance, represents a significant advancement in the ongoing effort to prevent diseases caused by the bacterium Streptococcus pneumoniae. This report provides an exhaustive analysis of Vaxneuvance, covering its composition, mechanism of action, clinical development, safety profile, regulatory status, and its strategic position within the global pneumococcal vaccination landscape.

Developed by Merck, Vaxneuvance is designed to provide broader protection than its predecessor, the 13-valent pneumococcal conjugate vaccine (PCV13). It includes all 13 serotypes from PCV13 and adds two additional, epidemiologically significant serotypes, 22F and 33F, which have been responsible for a substantial portion of residual invasive pneumococcal disease (IPD) in both children and adults.[1]

The vaccine's approval was supported by a robust clinical development program involving both pediatric and adult populations. These trials consistently demonstrated that Vaxneuvance elicits an immune response that is non-inferior to PCV13 for the 13 shared serotypes. Critically, the studies also showed a statistically superior immune response for the two new serotypes (22F and 33F) and for serotype 3, a persistent cause of severe disease despite its inclusion in PCV13.[3] The safety profile of Vaxneuvance was found to be comparable to that of PCV13 across all age groups, a crucial factor for its widespread adoption.[6]

Vaxneuvance is indicated for active immunization against invasive pneumococcal disease in individuals from 6 weeks of age and older.[3] This broad indication covers the routine 4-dose infant immunization series, catch-up schedules for children and adolescents, and a single-dose administration for adults.[9] In the complex landscape of pneumococcal vaccination, Vaxneuvance serves as a direct alternative to other conjugate vaccines and as a key component of a sequential vaccination strategy with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for certain adult populations.[10]

The vaccine has achieved key regulatory milestones, securing approval from the U.S. Food and Drug Administration (FDA), the European Commission (EC), and Australia's Therapeutic Goods Administration (TGA).[2] In the United States, it is recommended by the Advisory Committee on Immunization Practices (ACIP) and is included in the Vaccines for Children (VFC) program, ensuring broad access.[14] This monograph synthesizes the comprehensive evidence base for Vaxneuvance, positioning it as a pivotal tool in public health for the prevention of pneumococcal disease.

Introduction to Pneumococcal Disease and the Evolution of Conjugate Vaccines

The Pathogen: Streptococcus pneumoniae and its Clinical Burden

Streptococcus pneumoniae, or pneumococcus, is a gram-positive bacterium that remains a leading cause of morbidity and mortality worldwide.[16] It is responsible for a wide spectrum of illnesses, ranging from relatively mild, non-invasive infections such as acute otitis media (ear infections) and sinusitis to severe, life-threatening invasive pneumococcal disease (IPD).[18] IPD occurs when the bacterium invades normally sterile body sites, leading to conditions such as bacteremia (bloodstream infection), meningitis (infection of the membranes surrounding the brain and spinal cord), and bacteremic pneumonia.[18] The consequences of IPD can be devastating, resulting in long-term sequelae like brain damage or hearing loss, and in many cases, death.[18]

While anyone can contract pneumococcal disease, the burden is disproportionately borne by vulnerable populations. Young children under the age of five, older adults (particularly those aged 65 and over), and individuals of any age with certain chronic health conditions (e.g., heart, lung, or liver disease; diabetes) or immunocompromising conditions (e.g., HIV infection, malignancy, asplenia) are at the highest risk for severe outcomes.[5]

The Concept of Serotypes and Rationale for Polyvalent Vaccines

The primary virulence factor of S. pneumoniae is its polysaccharide capsule, a complex sugar coating that protects the bacterium from the host's immune system, particularly from phagocytosis.[16] The immune system's ability to generate antibodies against this capsule is the principal mechanism of protection.

There are over 100 structurally and immunologically distinct capsular types, known as serotypes.[16] However, a relatively small subset of these serotypes is responsible for the vast majority of human disease.[1] The distribution of these disease-causing serotypes can vary by geographic region, age group, and over time, partly due to the evolutionary pressure exerted by vaccination programs (a phenomenon known as serotype replacement). This epidemiological reality necessitates the development of polyvalent vaccines that target multiple serotypes simultaneously to provide broad protection against the most prevalent and virulent strains.[26]

Evolution of Pneumococcal Vaccination: From Polysaccharide to Conjugate Technology

The first widely used pneumococcal vaccine was the 23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax 23). This vaccine contains purified capsular polysaccharides from 23 different serotypes.[23] PPSV23 induces an immune response through a T-cell-independent mechanism, which involves the direct stimulation of B-cells to produce antibodies.[24] While effective in healthy adults, this type of immune response has significant limitations: it is poorly immunogenic in children under two years of age, whose immune systems cannot mount an effective response to polysaccharide antigens, and it fails to generate robust, long-lasting immunological memory.[11]

A transformative breakthrough in vaccinology was the development of conjugate technology. This process involves covalently linking the polysaccharide antigens to an immunogenic carrier protein, such as CRM197, a non-toxic variant of the diphtheria toxin.[1] This conjugation fundamentally alters the nature of the immune response. The protein-polysaccharide complex is recognized and processed by the immune system as a T-cell-dependent antigen.[24] This engagement of T-helper cells leads to a more robust and sophisticated immune response, characterized by high-affinity antibody production, isotype switching, and, most importantly, the generation of long-lasting memory B-cells. This T-cell-dependent memory is what enables a rapid and powerful booster response upon subsequent exposure and makes conjugate vaccines highly effective in infants, forming the cornerstone of modern pediatric immunization programs.[11]

The introduction of the first pneumococcal conjugate vaccine (PCV7) in 2000, followed by its successor PCV13 in 2010, dramatically reduced the incidence of IPD caused by vaccine serotypes in children and, through herd protection, in the broader community.[29] Each successive generation of vaccine expanded serotype coverage to address the changing epidemiology of the disease, setting the stage for the development of PCV15.

This evolutionary path of vaccine development relies heavily on a regulatory paradigm known as immunobridging. Since conducting large-scale, placebo-controlled efficacy trials becomes unethical once an effective vaccine exists, new vaccines are often licensed by demonstrating that the immune responses they generate are "non-inferior" to those of an established, effective vaccine.[28] PCV13 was licensed based on immunobridging to PCV7, and Vaxneuvance (PCV15) was subsequently licensed based on immunobridging to PCV13.[2] This "bridge to a bridge" approach is a pragmatic and necessary regulatory pathway. However, it requires careful consideration, as non-inferiority criteria permit a small margin of difference between vaccines. There is a theoretical possibility that a subtle, cumulative decline in immunogenicity for shared serotypes could occur over successive generations of vaccines. This possibility is underscored by observations of a numeric trend toward declining immunogenicity for shared serotypes as vaccine valency increases.[28] This context highlights the critical importance of robust post-marketing surveillance and real-world effectiveness studies to ensure that the protective efficacy inferred from immunobridging trials translates into sustained public health impact.

Vaxneuvance (PCV15): Product Profile and Mechanism of Action

Nomenclature and Identification

The vaccine is identified by its generic name, pneumococcal 15-valent conjugate vaccine (PCV15).[10] It is marketed globally by Merck under the brand name Vaxneuvance.[3] During its clinical development, it was referred to by the investigational code V114.[1]

Composition and Formulation

Vaxneuvance is supplied as a sterile suspension for intramuscular injection in a single-dose, 0.5 mL prefilled syringe.[17]

• Active Ingredients: Each 0.5 mL dose is composed of purified capsular polysaccharides from 15 distinct S. pneumoniae serotypes. The formulation contains 2.0 µg of polysaccharide for each of 14 serotypes and a higher dose of 4.0 µg for serotype 6B.[33] This differential dosing for serotype 6B is a feature shared with other conjugate vaccines and is designed to elicit a sufficient immune response for this specific serotype.
• Carrier Protein: All 15 polysaccharide antigens are individually conjugated to a carrier protein, CRM197. CRM197 is a non-toxic, genetically detoxified variant of diphtheria toxin, and each dose contains approximately 30 µg of this protein.[17]
• Adjuvant and Excipients: The vaccine is adsorbed onto an aluminum phosphate adjuvant (containing 125 µg of aluminum) to potentiate the immune response.[17] Inactive ingredients (excipients) include L-histidine, polysorbate 20, and sodium chloride, which serve to stabilize the formulation.[21] The final product does not contain preservatives, and the syringe components are not made with natural rubber latex.[17]

Targeted Serotypes and Rationale

Vaxneuvance provides protection against 15 pneumococcal serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F.[3] This formulation includes all 13 serotypes found in the predecessor vaccine, PCV13, ensuring continuity of protection against these established disease-causing strains.[1]

The primary innovation of PCV15 is the strategic addition of two serotypes: 22F and 33F.[1] The selection of these serotypes was not arbitrary but was based on extensive epidemiological surveillance data. Following the widespread implementation of PCV13, serotypes 22F and 33F emerged as significant causes of residual IPD in both children and adults globally.[2] In the pediatric population, serotypes 3, 22F, and 33F are collectively responsible for more than a quarter of all IPD cases, representing a substantial unmet medical need that Vaxneuvance was designed to address.[2]

Furthermore, the development of Vaxneuvance appears to have involved a targeted effort to improve upon a known limitation of its predecessor. Serotype 3 has remained a leading cause of severe pneumococcal disease, particularly in adults, despite its inclusion in PCV13.[5] This persistence suggests that the immune response elicited by PCV13 against serotype 3 may be suboptimal or wane more rapidly than for other serotypes. A key feature of Vaxneuvance, consistently demonstrated in clinical trials, is its ability to generate a superior immune response to serotype 3 compared to PCV13.[3] This specific immunological enhancement represents a significant potential clinical advantage, positioning Vaxneuvance not merely as an incremental expansion of coverage ("PCV13 + 2") but as a re-engineered vaccine designed to address a specific and persistent clinical challenge.

Immunological Mechanism of Action

Vaxneuvance functions via the established T-cell-dependent mechanism of conjugate vaccines. Following intramuscular injection, the polysaccharide-protein conjugate complexes are taken up by antigen-presenting cells (APCs).[24] These cells process the complex, presenting peptides derived from the CRM197 carrier protein on their surface via major histocompatibility complex (MHC) class II molecules. These peptide-MHC complexes are recognized by carrier-specific T-helper cells, leading to their activation.[24]

Simultaneously, B-cells with receptors that recognize the polysaccharide antigens also internalize the conjugate. They then present the same CRM197 peptides on their MHC class II molecules. When an activated T-helper cell recognizes this complex on the B-cell surface, it provides co-stimulatory signals ("T-cell help") to the B-cell.[24] This T-B cell collaboration is the critical step that drives a powerful and durable immune response, which includes:

• Opsonophagocytic Antibodies: The primary protective mechanism is the generation of high-titer, high-affinity functional antibodies (primarily IgG) against the targeted capsular polysaccharides. These antibodies bind to the surface of invading pneumococci, a process called opsonization. This "tags" the bacteria for recognition and engulfment by phagocytic cells like macrophages and neutrophils, leading to their destruction. This process, known as opsonophagocytic killing, is the key correlate of protection against pneumococcal disease.[1]
• Immunological Memory: The T-cell-dependent response leads to the differentiation of B-cells into long-lived plasma cells, which provide a sustained level of circulating antibodies, and memory B-cells. These memory cells persist for years and can be rapidly reactivated upon subsequent exposure to the pathogen, mounting a quick and potent anamnestic (booster) antibody response that prevents or mitigates disease.[24]
• Herd Protection: By inducing a strong mucosal immune response, conjugate vaccines like Vaxneuvance can reduce nasopharyngeal colonization with the vaccine serotypes. Since colonization of the upper respiratory tract is a necessary precursor for both disease development and person-to-person transmission, reducing carriage in vaccinated individuals decreases the overall circulation of these serotypes in the community. This confers indirect protection, or herd protection, to unvaccinated individuals, including infants too young to be fully vaccinated and other vulnerable persons.[29]

Clinical Development Program: Immunogenicity and Safety Evaluation

The licensure of Vaxneuvance was supported by a comprehensive clinical development program comprising multiple Phase II and Phase III randomized, double-blind, active-controlled trials. These studies were designed to evaluate the vaccine's immunogenicity, safety, and tolerability across diverse populations, including infants, children, adolescents, adults, and individuals with specific underlying health conditions.

Pivotal Trials in Pediatric Populations

The pediatric program for Vaxneuvance was designed to establish its suitability for routine infant immunization, catch-up vaccination, and use in high-risk groups, primarily by comparing its performance to the established standard of care, PCV13.

Immunogenicity Evaluation

Pivotal studies, such as V114-029, evaluated a 4-dose series of Vaxneuvance administered at 2, 4, 6, and 12-15 months of age compared to a 4-dose series of PCV13 in healthy infants.3 The primary immunogenicity endpoints were serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) and Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs), which are well-established immunological markers that correlate with protection against invasive pneumococcal disease.3

The key findings from these trials were:

• Non-inferiority for Shared Serotypes: Vaxneuvance successfully met the pre-specified non-inferiority criteria for the 13 serotypes it shares with PCV13. This was demonstrated by comparing IgG GMCs and the percentage of subjects achieving a pre-defined IgG threshold after the primary series and the toddler dose.[2] A meta-analysis of six randomized controlled trials (RCTs) confirmed non-inferiority for 12 of the 13 shared serotypes in infants.[7] This foundational result established that Vaxneuvance provides at least equivalent immunogenicity to the existing standard for the majority of targeted serotypes.
• Superiority for Key Serotypes: Secondary analyses consistently revealed a statistically superior immune response for Vaxneuvance compared to PCV13 for the two unique serotypes, 22F and 33F, as well as for the shared serotype 3.[2] This enhanced immunogenicity against three serotypes known to cause a significant burden of disease is a primary advantage of Vaxneuvance.

Interchangeability and Catch-Up Schedules

The clinical program also addressed practical questions regarding the vaccine's use in real-world settings. Study V114-027 demonstrated that Vaxneuvance can be used interchangeably within a vaccination series initiated with PCV13, showing that IgG GMCs for the shared serotypes were generally comparable regardless of the combination of vaccines used.6 Additional studies provided data supporting the immunogenicity and safety of Vaxneuvance when used in various catch-up schedules for older children and adolescents who were either unvaccinated or had an incomplete vaccination history.4

Clinical Trials in Adult Populations

The adult clinical development program for Vaxneuvance involved seven randomized, double-blind studies that enrolled over 7,400 individuals.[5] The study populations were diverse, including healthy adults aged 50 and older, adults aged 18 to 49 with and without risk factors for pneumococcal disease, and immunocompromised adults living with HIV.[5]

In pivotal trials comparing a single dose of Vaxneuvance to a single dose of PCV13 in pneumococcal vaccine-naïve adults, the results mirrored the pediatric findings. Vaxneuvance demonstrated non-inferior immune responses based on OPA GMTs for the 13 shared serotypes and elicited superior OPA GMTs for serotypes 3, 22F, and 33F.[5] Studies also evaluated the sequential administration of Vaxneuvance followed by PPSV23, demonstrating robust immune responses for all serotypes, which supports the ACIP recommendation for this regimen in certain adult populations.[43]

Use in Special Populations

Recognizing the heightened risk of pneumococcal disease in certain groups, the clinical development program included dedicated studies in special populations.

• Preterm Infants: Vaxneuvance is approved for use in preterm infants. As with other intramuscular vaccines, apnea (a temporary cessation of breathing) has been observed in some infants born prematurely. Therefore, the decision to vaccinate should be based on the infant's medical status and a careful assessment of the potential benefits and risks.[3]
• Immunocompromised Individuals: The vaccine has been shown to be immunogenic in children and adults with immunocompromising conditions.
• In children aged 6 to 17 years living with HIV, a single dose of Vaxneuvance elicited higher IgG GMCs for 8 of the 13 shared serotypes and for the two unique serotypes compared to a dose of PCV13.[23]
• Similarly, in children aged 5 to 17 years with sickle cell disease, Vaxneuvance produced higher IgG GMCs for 6 of the 13 shared serotypes and for the two unique serotypes.[23]
• The adult program also included individuals with HIV, supporting its use in this population.[5]

Safety and Tolerability Profile

Across the extensive clinical trial program, the safety and tolerability profile of Vaxneuvance was found to be comparable to that of PCV13.[4]

Contraindications

Vaxneuvance is contraindicated in individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine or to diphtheria toxoid.3

Warnings and Precautions

• Individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced antibody response to the vaccine.[3]
• The potential risk of apnea should be considered when administering the vaccine to infants born prematurely.[3]
• As with any injectable vaccine, appropriate medical treatment and supervision should be readily available in case of a rare anaphylactic event.[46]

Common Solicited Adverse Reactions

The most frequently reported adverse reactions were generally mild to moderate in severity and transient. The specific profile of reactions varied by age group and dosing schedule, as summarized in Table 1.

Table 1: Summary of Common Solicited Adverse Reactions by Age Group

Adverse Reaction	Infants (4-dose series, % range)	Children/Adolescents (2-17 yrs, single dose, %)	Adults (18-49 yrs, single dose, %)	Adults (≥50 yrs, single dose, %)
Local Reactions
Injection-site pain	25.9% – 40.3%	54.8%	75.8%	66.8%
Injection-site swelling	11.3% – 13.4%	20.9%	21.7%	15.4%
Injection-site erythema (Redness)	13.7% – 21.4%	19.2%	15.1%	10.9%
Injection-site induration (Hardening)	13.2% – 15.4%	6.8%	N/A	N/A
Systemic Reactions
Irritability	57.3% – 63.4%	N/A	N/A	N/A
Somnolence (Sleepiness)	24.2% – 47.5%	N/A	N/A	N/A
Fever (≥38.0°C)	13.3% – 20.4%	N/A	N/A	N/A
Decreased Appetite	14.1% – 19.0%	N/A	N/A	N/A
Fatigue	N/A	15.8%	34.3%	21.5%
Myalgia (Muscle Pain)	N/A	23.7%	28.8%	26.9%
Headache	N/A	11.9%	26.5%	18.9%
Arthralgia (Joint Pain)	N/A	N/A	12.7%	7.7%
Data compiled from sources.9 N/A indicates the reaction was not among the most commonly reported for that specific age group in the provided sources.

Approved Indications, Dosing, and Administration

General Indication

Vaxneuvance is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.[3] In the European Union, the approved indication for the pediatric population also explicitly includes the prevention of pneumonia and acute otitis media caused by

S. pneumoniae.[35]

Pediatric Dosing Regimens

The administration schedule for children and adolescents is tailored to their age and vaccination history.

• Routine Infant Series: The standard primary series for infants consists of four 0.5 mL doses, administered intramuscularly. The recommended schedule is at 2, 4, and 6 months of age, followed by a fourth (booster) dose at 12 through 15 months of age.[3]
• Catch-Up Schedules: For children who are unvaccinated or have fallen behind on their immunization schedule, specific catch-up regimens are recommended [9]:
• Age at first dose 7 through 11 months: A 3-dose series is recommended. The first two doses are given at least 4 weeks apart, and the third dose is given after the child's first birthday, at least 2 months after the second dose.
• Age at first dose 12 through 23 months: A 2-dose series is recommended, with the doses separated by at least 8 weeks.
• Age 2 through 17 years: A single dose is recommended.

Adult Dosing

For adults 18 years of age and older, Vaxneuvance is administered as a single 0.5 mL intramuscular dose.[8] The need for revaccination with a subsequent dose has not been established.[46]

Administration

Vaxneuvance is for intramuscular injection only.[9] Before administration, the prefilled syringe should be held horizontally and shaken vigorously to create a uniform, opalescent suspension.[9] The preferred injection site is the deltoid muscle of the upper arm in adults and older children, and the anterolateral aspect of the thigh in infants.[35]

Co-administration and Interchangeability

The clinical development program has provided data supporting the concomitant administration of Vaxneuvance with other routine vaccines. In pediatric populations, it can be given at the same time as other childhood vaccines.[2] In adults, it can be co-administered with the seasonal inactivated influenza vaccine.[5] When multiple vaccines are given at the same visit, they should always be administered at different injection sites.[48]

The vaccine is also approved for interchangeable use. A 4-dose pediatric series that was initiated with a lower valency pneumococcal conjugate vaccine, such as PCV13, can be completed with Vaxneuvance.[2]

Comparative Landscape of Pneumococcal Vaccines

The introduction of Vaxneuvance has added a new option to a complex and evolving landscape of pneumococcal vaccines. Its clinical utility is best understood by comparing it to the other key vaccines available: the 20-valent pneumococcal conjugate vaccine (PCV20, Prevnar 20) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax 23). This comparison reveals distinct technologies, serotype coverages, and strategic roles in public health recommendations.

The availability of both PCV15 and PCV20 for adults has led to a divergence in vaccination strategies, creating two distinct pathways recommended by bodies like the ACIP.[11] One path prioritizes operational simplicity and broad conjugate protection in a single administration (PCV20). The other path prioritizes maximizing the absolute number of serotypes covered by using a sequential, two-vaccine approach (PCV15 followed by PPSV23). This latter strategy accepts greater logistical complexity (two separate vaccinations) to gain protection against serotypes unique to PPSV23, which are estimated to cause 8% to 15% of IPD in at-risk adult populations.[11] The choice between these strategies reflects a nuanced balance between public health pragmatism and the pursuit of the most comprehensive immunological coverage possible.

Table 2: Comparative Analysis of Licensed Pneumococcal Vaccines

Feature	Vaxneuvance (PCV15)	Prevnar 20 (PCV20)	Pneumovax 23 (PPSV23)
Manufacturer	Merck 50	Pfizer 51	Merck 51
Vaccine Type	Conjugate 51	Conjugate 51	Polysaccharide 51
Carrier Protein	CRM197 29	CRM197 29	N/A
Mechanism	T-cell dependent, induces immunological memory 11	T-cell dependent, induces immunological memory 11	T-cell independent, induces limited/no memory 27
Total Serotypes	15 52	20 52	23 52
Serotypes Covered	1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F 29	1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F 29	1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F 23
Key Strategic Role	Provides broader coverage than PCV13. Used alone or as the conjugate "priming" dose in a sequential regimen with PPSV23 for adults.11	Provides the broadest conjugate protection in a single dose for adults, simplifying the vaccination schedule.11	Provides the widest serotype coverage. Used after a conjugate vaccine in certain high-risk populations to "broaden" protection.11
Serotypes unique to a vaccine compared to the others in the table are in bold. Serotype lists compiled from sources 29 and.23

PCV15 (Vaxneuvance) vs. PCV20 (Prevnar 20)

• Technology: Both Vaxneuvance and Prevnar 20 are advanced conjugate vaccines that utilize the same underlying technology, conjugating capsular polysaccharides to the CRM197 carrier protein to elicit a T-cell-dependent immune response.[29]
• Serotype Coverage: The primary distinction is the number of serotypes covered. PCV20 includes all 15 serotypes present in Vaxneuvance, plus an additional five serotypes: 8, 10A, 11A, 12F, and 15B.[23]
• Clinical Strategy Implications: This difference in valency directly impacts their roles in adult vaccination strategies. PCV20 is positioned as a single-dose solution that provides the broadest available conjugate protection, eliminating the need for a subsequent PPSV23 dose.[11] In contrast, PCV15 serves as an alternative conjugate vaccine that, when used in certain adult populations, is followed by a dose of PPSV23 to achieve maximum serotype coverage.[11]

PCV15 (Vaxneuvance) vs. PPSV23 (Pneumovax 23)

• Technology: This comparison highlights the fundamental difference between the two main types of pneumococcal vaccines. PCV15's conjugate technology induces a robust, memory-generating immune response effective in all age groups. PPSV23's polysaccharide technology induces a T-cell-independent response that is less effective in immunocompromised individuals and infants and does not produce a durable memory response.[11]
• Serotype Coverage: PPSV23 covers a greater number of serotypes (23) than PCV15 (15). PPSV23 includes 10 serotypes not found in PCV15 (2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 19A, 20). Conversely, PCV15 contains serotype 6A, which is not in PPSV23.[23]
• Clinical Strategy Implications: These two vaccines are not considered competitors but rather complementary tools in a comprehensive vaccination strategy for high-risk adults. The recommended approach is to first administer the conjugate vaccine (PCV15) to "prime" the immune system and establish a strong memory response. This is followed by a dose of PPSV23 to "broaden" the protection to include the additional serotypes it covers.[10] The initial conjugate dose is thought to enhance the response to the subsequent polysaccharide vaccine.

Global Regulatory Approvals and Public Health Recommendations

United States

• Food and Drug Administration (FDA) Approval: Vaxneuvance received its initial FDA approval on July 16, 2021, for use in adults aged 18 years and older.[5] Following a Priority Review of the pediatric clinical trial data, the FDA expanded the indication on June 22, 2022, to include individuals from 6 weeks through 17 years of age.[2]
• Advisory Committee on Immunization Practices (ACIP) Recommendations: The ACIP, which provides vaccination guidance for the Centers for Disease Control and Prevention (CDC), has incorporated Vaxneuvance into its official recommendations.
• Pediatric Use: The ACIP recommends Vaxneuvance as an option for pneumococcal conjugate vaccination in children under 19 years of age. It can be used interchangeably with PCV13 and follows the same dosing and schedules.[6]
• Adult Use: For adults aged 65 years and older, and for adults aged 19-64 with underlying medical conditions or other risk factors, the ACIP recommends one of two primary strategies: either a single dose of PCV20, or a single dose of PCV15 followed at a later interval by a dose of PPSV23.[11]
• Vaccines for Children (VFC) Program: In a crucial step for ensuring equitable access, the ACIP unanimously voted to include Vaxneuvance in the VFC program. This federally funded program provides vaccines at no cost to eligible children who might not otherwise be vaccinated because of inability to pay.[14]

Europe

• European Medicines Agency (EMA) and European Commission (EC) Approval: Vaxneuvance underwent a centralized review process in the European Union. Following a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) in October 2021, the European Commission granted marketing authorization for adults (≥18 years) on December 15, 2021.[12] The pediatric indication, for use in infants, children, and adolescents from 6 weeks to less than 18 years of age, was subsequently approved on October 24, 2022.[38]
• National Immunization Programs (NIPs): The EC approval allows Vaxneuvance to be marketed in all 27 EU member states, as well as Iceland, Norway, and Lichtenstein. However, its inclusion in national immunization programs is determined by individual member states based on their own health technology assessments and official recommendations.[35] The provided documentation does not confirm its specific funding status within the NIPs of major European countries.[35]

Australia

• Therapeutic Goods Administration (TGA) Approval: The TGA, Australia's regulatory body, approved Vaxneuvance for use in adults aged 18 years and older on January 12, 2022.[13] The approval was later expanded to include the pediatric population from 6 weeks of age.[26] As a new biological entity, Vaxneuvance is subject to enhanced safety monitoring under the TGA's Black Triangle Scheme for five years following its initial supply in Australia.[13]
• Australian Technical Advisory Group on Immunisation (ATAGI) Recommendations and NIP Status: ATAGI provides national recommendations on the use of vaccines.
• ATAGI includes PCV15 as a recommended option for adults who require pneumococcal vaccination, alongside PCV13 and PCV20.[33]
• However, a critical distinction is its funding status. As of the latest available information, Vaxneuvance (15vPCV) is not funded under Australia's National Immunisation Program (NIP) for adults and is only available as a private market vaccine.[25]
• For the pediatric population, the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended Vaxneuvance for NIP listing based on its cost-effectiveness compared to PCV13. However, final government approval and implementation of this recommendation are still required before it becomes a funded option for children.[57]

Synthesis and Future Directions

The 15-valent pneumococcal conjugate vaccine, Vaxneuvance, represents a strategically designed evolution in the fight against pneumococcal disease. It builds directly upon the proven success of its predecessor, PCV13, by maintaining non-inferior immunogenicity for the 13 shared serotypes while addressing key areas of unmet medical need. Its principal advantages lie in the demonstrably superior immune responses it elicits against three epidemiologically critical serotypes—22F, 33F, and the particularly resilient serotype 3—which collectively account for a significant portion of the remaining burden of invasive pneumococcal disease. This targeted improvement, coupled with a safety profile that is reassuringly comparable to the well-established PCV13, underpins its value proposition for both pediatric and adult populations.

The introduction of Vaxneuvance, alongside the higher-valency PCV20 and PCV21, has fundamentally reshaped pneumococcal immunization strategies, particularly for adults.[16] Clinicians and public health bodies now have multiple evidence-based options, leading to more nuanced recommendations that balance logistical simplicity with the breadth of serotype coverage.

The future of pneumococcal disease prevention will be shaped by several key factors. First, the pathogen's capacity for adaptation through serotype replacement—whereby non-vaccine serotypes increase in prevalence following the successful suppression of vaccine serotypes—necessitates continuous, robust epidemiological surveillance. This surveillance will be critical for informing the development of next-generation vaccines with even broader coverage. Second, the reliance on immunobridging for vaccine licensure underscores the importance of post-marketing studies to confirm the real-world effectiveness of Vaxneuvance and other new vaccines.[28] These studies will be essential to validate that the superior immunogenicity observed in clinical trials translates into superior protection against clinical disease endpoints. As Vaxneuvance becomes more widely integrated into global immunization programs, its impact on the incidence and epidemiology of pneumococcal disease will be closely monitored, guiding the next phase in this ongoing public health success story.

Works cited

1. Pneumococcal conjugate vaccine - Wikipedia, accessed September 23, 2025, https://en.wikipedia.org/wiki/Pneumococcal_conjugate_vaccine
2. FDA Approves Pneumococcal 15-Valent Conjugate Vaccine for Pediatric Use, accessed September 23, 2025, https://www.uspharmacist.com/article/fda-approves-pneumococcal-15valent-conjugate-vaccine-for-pediatric-use
3. VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) | Official HCP Site - MerckVaccines.com, accessed September 23, 2025, https://www.merckvaccines.com/vaxneuvance-pediatric/
4. Pneumococcal 15-Valent Conjugate Vaccine Provides Heightened Protection Against Certain Serotypes Compared With PCV13 | Pharmacy Times, accessed September 23, 2025, https://www.pharmacytimes.com/view/pneumococcal-15-valent-conjugate-vaccine-provides-heightened-protection-against-certain-serotypes-compared-with-pcv13
5. Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes, accessed September 23, 2025, https://www.merck.com/news/merck-announces-u-s-fda-approval-of-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-adults-18-years-and-older-caused-by-15-serot/
6. GRADE: 15-valent pneumococcal conjugate vaccine (PCV15) use in children aged - CDC, accessed September 23, 2025, https://www.cdc.gov/acip/grade/pneumo-PCV15-child.html
7. Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis - PMC - PubMed Central, accessed September 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11685527/
8. vaxneuvance_pi.pdf - Merck.com, accessed September 23, 2025, https://www.merck.com/product/usa/pi_circulars/v/vaxneuvance/vaxneuvance_pi.pdf
9. Package Insert VAXNEUVANCE | FDA, accessed September 23, 2025, https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert-VAXNEUVANCE.pdf
10. Pneumococcal Conjugate Vaccine (15-Valent) | Drug Lookup | Pediatric Care Online, accessed September 23, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/7654/Pneumococcal-Conjugate-Vaccine-15-Valent
11. Simplifying Pneumococcal Immunizations for Adults - AAFP, accessed September 23, 2025, https://www.aafp.org/pubs/afp/issues/2022/0600/p580.html
12. European Commission Approves Merck's VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older, accessed September 23, 2025, https://www.merck.com/news/european-commission-approves-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-individuals-18-years-of-age-and-older/
13. Vaxneuvance | Therapeutic Goods Administration (TGA), accessed September 23, 2025, https://www.tga.gov.au/resources/auspmd/vaxneuvance
14. CDC's ACIP Unanimously Votes to Provisionally Recommend Use of Merck's VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children - Merck.com, accessed September 23, 2025, https://www.merck.com/news/cdcs-acip-unanimously-votes-to-provisionally-recommend-use-of-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-as-an-option-for-pneumococcal-vaccination-in-infa/
15. Resources for VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) and the Vaccines For Children (VFC) Program, accessed September 23, 2025, https://www.vaxneuvance.com/pediatrics/caregiver-resources/
16. The New Era of Pneumococcal Vaccination in Adults: What Is Next? - MDPI, accessed September 23, 2025, https://www.mdpi.com/2076-393X/13/5/498
17. July 16, 2021 Summary Basis for Regulatory Action - VAXNEUVANCE - FDA, accessed September 23, 2025, https://www.fda.gov/media/151201/download
18. Pneumococcal Conjugate Vaccine (Interim) VIS - CDC, accessed September 23, 2025, https://www.cdc.gov/vaccines/hcp/current-vis/pneumococcal-conjugate.html
19. Pneumococcal vaccine - NHS, accessed September 23, 2025, https://www.nhs.uk/vaccinations/pneumococcal-vaccine/
20. Pneumococcal Conjugate Vaccine: MedlinePlus Drug Information, accessed September 23, 2025, https://medlineplus.gov/druginfo/meds/a610017.html
21. Frequently Asked Questions About VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine), accessed September 23, 2025, https://www.vaxneuvance.com/pediatrics/frequently-asked-questions/
22. Your Child's Vaccines: Pneumococcal Vaccines (PCV, PPSV) | Nemours KidsHealth, accessed September 23, 2025, https://kidshealth.org/en/parents/pneumococcal-vaccine.html
23. Pneumococcal Vaccine - StatPearls - NCBI Bookshelf, accessed September 23, 2025, https://www.ncbi.nlm.nih.gov/books/NBK507794/
24. Conjugation Mechanism for Pneumococcal Glycoconjugate Vaccines: Classic and Emerging Methods - MDPI, accessed September 23, 2025, https://www.mdpi.com/2306-5354/9/12/774
25. Pneumococcal vaccines – frequently asked questions (FAQs) | NCIRS, accessed September 23, 2025, https://ncirs.org.au/ncirs-fact-sheets-faqs-and-other-resources/pneumococcal-vaccines-frequently-asked-questions-faqs
26. Pneumococcal 15-valent and 20-valent conjugate vaccines for prevention of pneumococcal disease - PMC, accessed September 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10751082/
27. Pneumococcal Vaccines Update for 2023 - U.S. Pharmacist, accessed September 23, 2025, https://www.uspharmacist.com/article/pneumococcal-vaccines-update-for-2023
28. Immunogenicity of Current and Next-Generation Pneumococcal Conjugate Vaccines in Children: Current Challenges and Upcoming Opportunities, accessed September 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11103622/
29. About Pneumococcal Vaccines: For Providers - CDC, accessed September 23, 2025, https://www.cdc.gov/vaccines/vpd/pneumo/hcp/about-vaccine.html
30. Pneumococcal Conjugate Vaccines Patient Drug Record | NIH - Clinical Info HIV.gov, accessed September 23, 2025, https://clinicalinfo.hiv.gov/en/drugs/pneumococcal-conjugate-vaccines/patient
31. Pneumococcal 15-valent conjugate vaccine (intramuscular route) - Side effects & uses, accessed September 23, 2025, https://www.mayoclinic.org/drugs-supplements/pneumococcal-15-valent-conjugate-vaccine-intramuscular-route/description/drg-20518750
32. VAXNEUVANCE® | Merck Canada, accessed September 23, 2025, https://www.merck.ca/en/wp-content/uploads/sites/20/2021/04/VAXNEUVANCE-PM_E.pdf
33. Pneumococcal disease - The Australian Immunisation Handbook, accessed September 23, 2025, https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/pneumococcal-disease
34. Vaxneuvance | The Australian Immunisation Handbook, accessed September 23, 2025, https://immunisationhandbook.health.gov.au/vaccines/vaxneuvance
35. Vaxneuvance | European Medicines Agency (EMA), accessed September 23, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/vaxneuvance
36. Patient Information - VAXNEUVANCE - FDA, accessed September 23, 2025, https://www.fda.gov/media/150818/download
37. VAXNEUVANCE - FDA, accessed September 23, 2025, https://www.fda.gov/vaccines-blood-biologics/vaccines/vaxneuvance
38. VAXNEUVANCE 15 Pneumococcal Vaccine - Vax-Before-Travel, accessed September 23, 2025, https://www.vax-before-travel.com/vaccines/vaxneuvance-15-pneumococcal-vaccine
39. The immunological mechanisms that control pneumococcal carriage - PMC, accessed September 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5739485/
40. Clinical Review Memo, July 14, 2021 - VAXNEUVANCE - FDA, accessed September 23, 2025, https://www.fda.gov/media/151199/download
41. Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. ..., accessed September 23, 2025, https://www.cdc.gov/mmwr/volumes/71/wr/mm7137a3.htm
42. EC grants approval to Merck's pneumonia vaccine for use in adults, accessed September 23, 2025, https://www.pharmaceutical-technology.com/news/ec-approval-merck-pneumonia-vaccine/
43. GRADE: 15-valent pneumococcal conjugate vaccine (PCV15) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) for adults aged ≥65 years | ACIP | CDC, accessed September 23, 2025, https://www.cdc.gov/acip/grade/pneumo-PCV15-PPSV23-age-based.html
44. Safety and Tolerability Profiles for VAXNEUVANCE ..., accessed September 23, 2025, https://www.merckvaccines.com/vaxneuvance-pediatric/safety-tolerability/
45. FAQs About VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) for Patients, accessed September 23, 2025, https://www.merckvaccines.com/vaxneuvance-pediatric/frequently-asked-questions/
46. Vaxneuvance, INN-Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed), accessed September 23, 2025, https://ec.europa.eu/health/documents/community-register/2021/20211213153806/anx_153806_en.pdf
47. European Commission Expands Merck's VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents, accessed September 23, 2025, https://www.merck.com/news/european-commission-expands-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-indication-to-include-infants-children-and-adolescents/
48. Vaxneuvance, INN-Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed), accessed September 23, 2025, https://id-ea.org/wp-content/uploads/2022/10/vaxneuvance-epar-product-information_en.pdf
49. Pneumococcal Vaccines - Medical Clinical Policy Bulletins | Aetna, accessed September 23, 2025, https://www.aetna.com/cpb/medical/data/1_99/0037.html
50. Vaxneuvance (pneumococcal 15-valent conjugate vaccine) FDA Approval History - Drugs.com, accessed September 23, 2025, https://www.drugs.com/history/vaxneuvance.html
51. Table 3, Comparison of Pneumococcal Vaccines Authorized for Use in Adults in Canada, accessed September 23, 2025, https://www.ncbi.nlm.nih.gov/books/NBK608471/table/t03/
52. Types of Pneumococcal Vaccines | Pneumococcal | CDC, accessed September 23, 2025, https://www.cdc.gov/pneumococcal/vaccines/types.html
53. Protocol for Pneumococcal Vaccines PCV20 (Prevnar 20®), PCV15 (VAXNEUVANCE™), PCV13 (Prevnar 13®) and Pneumococcal Polysaccharide Vaccine: PPSV23 (Pneumovax®23) - Oregon.gov, accessed September 23, 2025, https://www.oregon.gov/pharmacy/Documents/PrevCare_Pneumococcal_v.10.2023.pdf
54. Did You Know? Updated Pneumococcal Recommendations for Adults (as of August 2022), accessed September 23, 2025, https://www.hdrxservices.com/did-you-know-updated-pneumococcal-recommendations-for-adults-as-of-august-2022/
55. Merck Wins Key FDA Approval for Pediatric Pneumococcal Vaccine - BioSpace, accessed September 23, 2025, https://www.biospace.com/fda-approves-merck-s-pneumocal-disease-vaccine-for-infants-and-children
56. Australian public assessment report for Vaxneuvance - Therapeutic Goods Administration (TGA), accessed September 23, 2025, https://www.tga.gov.au/sites/default/files/2022-10/auspar-vaxneuvance-20221012.pdf
57. Vaxneuvance gets NIP backing from PBAC - Medical Republic, accessed September 23, 2025, https://www.medicalrepublic.com.au/vaxneuvance-gets-nip-backing-from-pbac/17155
58. Capvaxive – A 21-Valent Pneumococcal Conjugate Vaccine | The Medical Letter Inc., accessed September 23, 2025, https://secure.medicalletter.org/TML-article-1713a
59. Possible Side Effects of VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine), accessed September 23, 2025, https://www.vaxneuvance.com/pediatrics/possible-side-effects/